Abstract
As life expectancy increases, the number of patients with diabetes over the age of 65 is increasing. This population primarily requires safe and simple treatment.
Gliptins, as high-quality antidiabetics, meet these requirements to the highest degree. The simplicity of administration, the practical absence of side effects and especially the minimal risk of hypoglycemia, fully sufficient effectiveness and cardiovascular safety are particularly important for use in therapy for elderly diabetics.
Sufficiently preserved insulin secretion is required to achieve the maximum effect. According to the SPC, they can be used in virtually any combination with other antidiabetic drugs.